1Y Close · As of Aug 26, 2026
Aptabio Therapeutics operates in the Professional Services sector.
Legal name: Aptabio Therapeutics Inc.
In fiscal year 2025, Aptabio Therapeutics (293780) reported revenue of 3.7 billion KRW, up 10.0% from 3.4 billion KRW a year earlier.
Operating profit was -15.8 billion KRW and net income was -16.3 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 170.0 billion KRW, with a P/B of 3.60.
These figures can be verified in the DART filing (receipt no. 20260323001542).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 3.7B | -15.8B | -16.3B |
| 2024 | 3.4B | -18.9B | -29.4B |
| 2023 | 324M | -16.4B | -12.1B |
| 2022 | 48M | -9.5B | -10.6B |
| 2021 | 224M | -11.4B | -10.7B |
Recent Filings
Early CB Acquisition (Including Overseas CB)
Semi-Annual Report (2026.06)
Checks
2 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Early CB Acquisition (Including Overseas CB) |
| 2026-08-14 | Semi-Annual Report (2026.06) |